Mounjaro (tirzepatide) has become one of the most sought-after weight loss injections in 2026, offering dual GIP/GLP-1 receptor agonism that delivers superior fat loss, glycemic control, and cardiometabolic improvements compared to single GLP-1 agonists. Approved in the United States, United Kingdom, Germany, France, Netherlands, Switzerland, Finland, Austria, Canada, Australia, and an increasing number of markets, […]